Germany Takes a Major Step Toward Access to TK2d Therapy
2 Sep, 2026
A significant milestone has been reached for families affected by TK2d: Germany has now formally recognised Kygevvi®, the first disease‑specific […]...
Strengthening Connections: IMP’s Ambassador Meetings
2 Sep, 2026
IMP has begun hosting regular Ambassador Meetings, creating a welcoming space for representatives from our member organisations to connect, share updates, […]...
LHON Webinar: 19 September – registration open
2 Sep, 2026
The LHON Awareness Day Webinar is approaching quickly, taking place on 19 September (13:00–15:00 CEST). This year’s theme — Best practices in LHON: stories […]...
Updated TK2d videos now available
2 Sep, 2026
Three new TK2d Awareness Day videos are being released in the lead‑up to 8 September, each sharing a deeply personal […]...
ERN‑RND Scientific Symposium: Registries for Rare Neurological Diseases
2 Sep, 2026
On 10 October 2026, the European Reference Network for Rare Neurological Diseases (ERN‑RND) will host a dedicated scientific symposium focused on […]...
Patient‑Focused Drug Development Meeting on POLG
2 Sep, 2026
A Landmark Moment for the POLG Community – 17 November 2026 On 17 November, MitoAction will host its first Patient‑Focused Drug Development […]...
Pretzel Therapeutics Answers Key Questions from the POLG Community
2 Sep, 2026
Following the POLG Foundation Summit, Pretzel Therapeutics has shared updated answers to community questions about PX578, their first‑in‑class investigational therapy for […]...
A Major Step Forward for the Global POLG Community
2 Sep, 2026
FDA clears PX578 to enter Phase 2 clinical testing At IMP, few moments bring more hope than seeing innovative science […]...
New Natural History Study Sheds Light on MNGIE
2 Sep, 2026
A new retrospective natural history study from the MitoCAMB team at the University of Cambridge offers important insights into mitochondrial neurogastrointestinal […]...
Germany Takes a Major Step Toward Access to TK2d Therapy
2 Sep, 2026
A significant milestone has been reached for families affected by TK2d: Germany has now formally recognised Kygevvi®, the first disease‑specific […]...
New Study Strengthens Patient‑Centred Endpoint Selection for KHENERFIN Phase 3 Trial
2 Sep, 2026
Khondrion has announced the publication of an important qualitative study in Orphanet Journal of Rare Diseases examining the lived experience […]...
The Effects of Hydrogen Sulfide, VOCs and Bioaerosols on People with Mitochondrial Disease
2 Sep, 2026
Written by Paula Morandi, Chair of IMP Why emissions from olive‑pomace fermentation pose a serious health risk The open‑air fermentation […]...
A note from the Chair: One Voice, 25 Nations — The Power of Our Global Umbrella
28 Aug, 2026
Paula Morandi, Chair of IMP When you hear the acronym IMP, what comes to mind? To many, International Mito Patients […]...
IMP Annual Meeting 2026 – Celebrating 15 years
10 Jul, 2026
The International Mito Patients (IMP) Annual Meeting 2026 brought together advocates, clinicians, researchers and partners from around the world to […]...
Registration is now open for the TK2d International Webinar 2026 .
10 Jul, 2026
TK2d across countries: diagnosis, multidisciplinary care and therapeutic pathways Registration is now open for the international webinar “TK2d Across Countries: Diagnosis, […]...
A word from our new member ASANOL
7 Jul, 2026
On 29 May, we had the opportunity to participate, for the first time as ASANOL, in the International Mito Patients meeting […]...
World Mitochondrial Disease Week 2026: Putting Mito on the Map
7 Jul, 2026
We’re delighted to announce the launch of this year’s World Mitochondrial Disease Week theme: “Putting Mito on the Map.” Members asked […]...
New Patient Journey for Primary Mitochondrial Myopathies Launched
7 Jul, 2026
IMP has worked with ERN EURO‑NMD and several leading patient organisations, including Mitocon, the Bulgarian Association for Neuromuscular Diseases, and […]...
New TK2d Early Symptom Reflection Tool Supports Better Clinical Conversations
30 Jun, 2026
UMDF, in collaboration with UCB, has launched a new resource designed specifically for people living with TK2d and those who […]...
The role of amino acids in some forms of mito
15 Jun, 2026
On May 9, 2026, International Mito Patients was represented at the Cognate Amino Acid for tRNA Synthetase Disorders Consortium meeting […]...
